http://journals.lww.com/bloodcoagulatio ... 99197.aspx
We performed a monocentric observational prospective study to evaluate coagulation activation and endothelial dysfunction parameters in patients with multiple sclerosis undergoing endovascular treatment for cerebro-spinal-venous insufficiency. Between February 2011 and July 2012, 144 endovascular procedures in 110 patients with multiple sclerosis and chronical cerebro-spinal venous insufficiency were performed and they were prospectively analyzed. Each patient was included in the study according to previously published criteria, assessed by the investigators before enrollment. Endothelial dysfunction and coagulation activation parameters were determined before the procedure and during follow-up at 1, 3, 6, 9, 12, 15 and 18 months after treatment, respectively. After the endovascular procedure, patients were treated with standard therapies, with the addition of mesoglycan. Fifty-five percent patients experienced a favorable outcome of multiple sclerosis within 1 month after treatment, 25% regressed in the following 3 months, 24.9% did not experience any benefit. In only 0.1% patients, acute recurrence was observed and it was treated with high-dose immunosuppressive therapy. No major complications were observed.
Coagulation activation and endothelial dysfunction parameters were shown to be reduced at 1 month and stable up to 12-month follow-up, and they were furthermore associated with a good clinical outcome. Endovascular procedures performed by a qualified staff are well tolerated; they can be associated with other currently adopted treatments. Correlations between inflammation, coagulation activation and neurodegenerative disorders are here supported by the observed variations in plasma levels of markers of coagulation activation and endothelial dysfunction.
The first question I asked Jeff's neuro was "why was his blood hypercoagulated?" It would take much more unraveling to learn about hypoxia, the coagulation cascade and endothelial dysfunction. So glad this is now being monitored after CCSVI treatment. We've seen the same benefit for Jeff---still, five years later, his c-reactive protein, SED rate and other endothelial markers are great.
Here's more on the coagulation cascade and endothelial dysfunction. This connection to MS is not new. Dr. Swank noted it in the 1950s. We're getting there.
http://ccsviinms.blogspot.com/2014/03/b ... tters.html